ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

2022 R&D Spending and Intensity Benchmarks

By: PRLog

VIRGINIA BEACH, Va. - June 12, 2023 - PRLog -- According to a newly released study from Schonfeld & Associates, Inc., R&D Ratios & Budgets, the pharmaceutical industry continued to be the biggest R&D investor in fiscal 2022 with budgets of drug companies increasing by 8% to $171 billion. Software companies contributed a total of over $200 billion to this investment pool.

The biggest single R&D investor in 2022 was Alphabet at over $39 billion, followed by Meta at $35 billion, and then Microsoft and Apple at over $25 billion each. Firms involved with digital content are investing much more heavily than those in more traditional arenas.

Pharmaceutical firms continued significant R&D spending in 2022. Johnson & Johnson, the top spender at $15.4 billion, is followed by Merck, Pfizer, Novartis, Astrazeneca and Bristol Myers Squibb, each spending over $9 billion. The biotech industry, led by Gilead, grew R&D by just 1% to over $35 billion. Electromedical apparatus makers, led by Medtronic, spent a total of over $3.8 billion, an increase of over ten percent.

R&D budgets of semiconductor makers grew to over $68 billion, an increase of 21.5%. Intel had the largest R&D budget, $17.5 billion, a 15% increase over 2021. R&D budgets of the industries that are major suppliers to the infrastructure of the Internet cloud continue increased R&D spending.

The 2022 R&D spending of the automotive industry, led by General Motors, Toyota, Ford and Honda each spending over $7 billion, was up over 24% from the 2021 total with industry revenues up 38%.

About the Study

R&D Ratios & Budgets
contains fiscal 2021 and 2022 R&D spending, 2022 revenue and 2022 R&D intensity ratio, as well as annual growth rates in R&D spending and sales for over 2,800 firms. Over 280 industry summaries of the same information are provided. The study reports for each company a low and high value for the R&D-to-sales ratio (also known as R&D intensity) for the last five years to indicate stability of R&D spending.

R&D Ratios & Budgets is used for budget planning, monitoring competition, identifying joint venture partners, and spotting acquisition candidates.

The 2023 edition of the PDF report is $ 395 and the report along with Excel datafiles is $ 495. Contact Schonfeld & Associates, Inc., 1932 Terramar Lane, Virginia Beach, VA 23456. Call for more information: 800-205-0030 or visit the company's web site for immediate download at www.saiBooks.com under Area of Expertise: Research & Development Spending.

Contact
Carol J. Greenhut
***@saibooks.com

Photos: (Click photo to enlarge)

Schonfeld & Associates, Inc. Logo R&D Intensity By Industry Sector R&D Growth by Country Sample Page R&D Ratios & Budgets

Read Full Story - 2022 R&D Spending and Intensity Benchmarks | More news from this source

Press release distribution by PRLog

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.